For pediatric patients with growth failure due to inadequate secretion of endogenous growth hormone (GH) and Prader-Willi Syndrome; short stature associated with Noonan Syndrome, Turner Syndrome, and children born small for gestational age; idiopathic short stature; and for the replacement of endogenous GH in adults with growth hormone deficiency (GHD). Please see full indications.
The #1 prescribed growth hormone therapy in the U.S.1
Norditropin® (somatropin) is preloaded in FlexPro® pens and is the only growth hormone therapy approved for 7 indications.2-8
The #1 prescribed once-daily growth hormone therapy1,a
Norditropin® (somatropin) injection is available as FlexPro® prefilled pens and is the only daily growth hormone therapy approved for 7 indications.2-8
aBased on data from Komodo Sentinel as of February 2026.
William, age 4, born with GHD
The #1 prescribed once-daily growth hormone therapy1,a
Norditropin® (somatropin) injection is available as FlexPro® prefilled pens and is the only daily growth hormone therapy approved for 7 indications.2-8
aBased on data from Komodo Sentinel as of February 2026.
Achieve treatment goals2
Proven safety and efficacy2,9
The safety and efficacy of Norditropin® have been evaluated in clinical studies, as well as an observational study in a real-world setting (originally a post-marketing registry).2,9,b
bThe ANSWER Program was originally a post-marketing registry of adults and pediatric patients treated with Norditropin® as prescribed by their physician and according to routine clinical practice. Since it did not investigate treatment specifics, it was developed into a non-interventional, observational study that allowed evaluation of the safety and effectiveness of Norditropin® in a real-world setting in the United States.9
Our calculators can help estimate height velocity and other metrics used in clinical practice. For US health care professionals only.
Our calculators can help estimate height velocity and other metrics used in clinical practice. For US health care professionals only.
Co-pay assistance is available
Eligible patients may pay as little as $0 per calendar year for their supply of Norditropin® (with an annual maximum cap of $1,500 per calendar year).
Co-pay assistance is available
Eligible patients may pay as little as $0 per calendar year for their supply of Norditropin® (with an annual maximum cap of $1,500 per calendar year).
Looking for a weekly option for your patient instead of daily?
NEW INDICATIONS! Sogroya® is the first and only LAGH approved for GHD and 3 other specific pediatric growth-related conditions10
Sogroya® is indicated for the replacement of endogenous growth hormone in adults with growth hormone deficiency (GHD) and for the treatment of pediatric patients aged 2.5 years and older with: growth failure due to inadequate secretion of endogenous growth hormone (GH), short stature born Small for Gestational Age (SGA) and with no catch-up growth by 2 years of age, growth failure associated with Noonan Syndrome (NS), and Idiopathic Short Stature (ISS).10
Important Safety Information
Contraindications
Sogroya® is contraindicated in patients with:
acute critical illness after open-heart surgery, abdominal surgery, multiple accidental trauma, or acute respiratory failure because of the risk of increased mortality with use of Sogroya® hypersensitivity to Sogroya® or any of its excipients. Systemic hypersensitivity reactions have been reported postmarketing with somatropin pediatric patients with closed epiphyses active malignancy active proliferative or severe non-proliferative diabetic retinopathy pediatric patients with Prader-Willi syndrome who are severely obese, have a history of upper airway obstruction or sleep apnea, or have severe respiratory impairment due to risk of sudden death
Important Safety Information Continued
Please see Sogroya® Prescribing Information.
Have you created your novoMEDLINKTM account?
Sign up now to receive news about growth-related disorders and relevant product updates from Novo Nordisk.
References:
Data on file. Novo Nordisk Inc; Plainsboro, NJ. Based on Komodo Sentinel as of February 2026. Norditropin® [prescribing information]. Plainsboro, NJ: Novo Nordisk Inc. Nutropin AQ® [prescribing information]. San Francisco, CA: Genentech, Inc; 2016. Genotropin® [prescribing information]. New York, NY: Pharmacia & Upjohn Co; 2019. Humatrope® [prescribing information]. Indianapolis, IN: Eli Lilly & Co; 2019. Saizen® [prescribing information]. Rockland, MA: EMD Serono, Inc; 2020. Omnitrope® [prescribing information]. Princeton, NJ: Sandoz, Inc; 2019. Zomacton® [prescribing information]. Parsippany, NJ: Ferring Pharmaceuticals, Inc; 2018. Data on file. Novo Nordisk Inc; Plainsboro, NJ. Sogroya® [prescribing information]. Plainsboro, NJ: Novo Nordisk Inc.